-
Partial volume correction improves theranostic 124I/131I-CLR1404 tumor dosimetry in xenograft models of head and neck cancer
Authors:
Ian R. Marsh,
Chunrong Li,
Joseph Grudzinski,
Justin Jeffery,
Colin Longhurst,
David P. Adam,
Reinier Hernandez,
Jamey P. Weichert,
Paul M. Harari,
Bryan P. Bednarz
Abstract:
Combination radiopharmaceutical and external beam radiotherapy offers the potential to diminish locoregional toxicity that remains dose-limiting in the conventional treatment paradigm for recurrent head and neck cancer (HNC). In this study, we investigated the tumor targeting capacity of 131I-CLR1404 (CLR 131) in various HNC xenograft mouse models and the impact of partial volume correction on the…
▽ More
Combination radiopharmaceutical and external beam radiotherapy offers the potential to diminish locoregional toxicity that remains dose-limiting in the conventional treatment paradigm for recurrent head and neck cancer (HNC). In this study, we investigated the tumor targeting capacity of 131I-CLR1404 (CLR 131) in various HNC xenograft mouse models and the impact of partial volume correction on theranostic dosimetry based on 124I-CLR1404 (CLR 124) PET/CT imaging. Methods: Mice bearing flank tumor xenograft models of HNC (6 murine cell line- and 6 human patient-derived) were intravenously administered 6.5-9.1 MBq of CLR 124 and imaged five times over the course of six days using microPET/CT. In vivo tumor uptake of CLR 124 was assessed and partial volume corrections (PVC) for 124I were applied using a novel preclinical phantom. Using subject-specific theranostic dosimetry estimations for CLR 131 based on CLR 124 imaging, a discrete radiation dose escalation study was performed to evaluate tumor growth response to CLR 131 relative to a single fraction of XRT. Results: PET imaging demonstrated consistent tumor selective uptake and retention of CLR 124 across all HNC xenograft models. Peak uptake of 4.4 +/- 0.8% and 4.2 +/- 0.4% was observed in SCC-22B and UW-13, respectively. PVC application increased uptake measures by 47-188% and reduced absolute differences between in vivo and ex vivo uptake measurements from 3.3 to 1.0 %IA/g. Tumor dosimetry averaged over all HNC models was 0.85 +/- 0.27 Gy/MBq (1.58 +/- 0.46 Gy/MBq with PVC). Therapeutic CLR 131 studies demonstrated a variable, but linear relationship between CLR 131 radiation dose and tumor growth delay (p < 0.05). Conclusion: CLR 131 demonstrated tumoricidal capacity in preclinical HNC tumor models and the theranostic pairing of CLR 124/131 presents a promising new treatment approach for personalizing administration of CLR 131.
△ Less
Submitted 13 February, 2022;
originally announced February 2022.
-
Validation of Monte Carlo Iodine-131 radiopharmaceutical dosimetry workflow using a 3D printed anthropomorphic head and neck phantom
Authors:
David P. Adam,
Joseph Grudzinski,
Ian Bormett,
Benjamin L. Cox,
Ian R. Marsh,
Tyler J. Bradshaw,
Paul Harari,
Bryan Bednarz
Abstract:
Purpose: In this study, we present the creation of an anthropomorphic, head and neck, nuclear medicine phantom and its characterization for the validation of a Monte Carlo, SPECT image based, Iodine-131 RPT dosimetry workflow.
Methods: 3D printing techniques were used to create the anthropomorphic phantom from a patient CT dataset. Three Iodine-131 SPECT/CT imaging studies were performed using a…
▽ More
Purpose: In this study, we present the creation of an anthropomorphic, head and neck, nuclear medicine phantom and its characterization for the validation of a Monte Carlo, SPECT image based, Iodine-131 RPT dosimetry workflow.
Methods: 3D printing techniques were used to create the anthropomorphic phantom from a patient CT dataset. Three Iodine-131 SPECT/CT imaging studies were performed using a homogeneous, Jaszczak, and an anthropomorphic phantom to quantify the SPECT images. The impact of collimator detector response (CDR) modeling and volume-based partial volume corrections (PVC) upon the absorbed dose was calculated using an image based, Geant4 Monte Carlo RPT dosimetry workflow and compared against a ground truth scenario. Finally, uncertainties were quantified in accordance with recent EANM guidelines.
Results: The 3D printed anthropomorphic phantom was an accurate re-creation of patient anatomy including bone. The extrapolated Jaszczak recovery coefficients were greater than that of the 3D printed insert (~22.8 ml) for both the CDR and non-CDR cases. Utilizing Jaszczak phantom PVCs, the absorbed dose was underpredicted by 0.7% and 4.9% without and with CDR, respectively. Utilizing anthropomorphic phantom RCs overpredicted the absorbed dose by 3% both with and without CDR. All dosimetry scenarios that incorporated PVC were within the calculated uncertainty of the activity. The uncertainties in the cumulative activity ranged from 25.6% to 113% for Jaszczak spheres ranging in volume from 0.5 ml to 16 ml.
Conclusion: The accuracy of Monte Carlo-based dosimetry for Iodine-131 RPT in head and neck cancer was validated with an anthropomorphic phantom. Future applications of the phantom could involve 3D printing and characterizing patient specific volumes for more personalized RPT dosimetry estimates.
△ Less
Submitted 3 February, 2022;
originally announced February 2022.
-
Dosimetric and Biologic Differences in Flattened and Flattening-Filter-Free Beam Treatment Plans
Authors:
Yue Yan,
Poonam Yadav,
Michael Bassetti,
Kaifang Du,
Daniel Saenz,
Paul Harari,
Bhudatt R. Paliwal
Abstract:
Purpose: To quantitatively compare the dosimetric and biologic differences in treatment plans from flattened and flattening-filter-free (FFF) beam for three anatomic cancer sites. Methods and Materials: Treatment plans with static intensity-modulated radiotherapy beams and volumetric modulated arc therapy beams were generated for 13 patients for both the flattened beam and the FFF beam of the True…
▽ More
Purpose: To quantitatively compare the dosimetric and biologic differences in treatment plans from flattened and flattening-filter-free (FFF) beam for three anatomic cancer sites. Methods and Materials: Treatment plans with static intensity-modulated radiotherapy beams and volumetric modulated arc therapy beams were generated for 13 patients for both the flattened beam and the FFF beam of the TrueBeam system. Beam energies of 6 MV and 10 MV were chosen for planning. A total of 104 treatment plans were generated in 13 patients. In order to analyze the biological effectiveness of treatment plans, dose volume histograms (DVH) were utilized. Flattened and FFF beam plans are quantitatively compared. Results: In head and neck cases, for VMAT plans, dose reduction in the FFF beam plans compared to the flattened beam in left cochlea, right submandibular gland and right parotid gland reached up to 2.36 Gy, 1.21 Gy and 1.45 Gy, respectively. Similarly, for static IMRT plans, the dose reduction of the FFF beam plans compared to the flattened beam plans for the same organs reached up to 0.34 Gy, 1.36 Gy and 1.46 Gy, respectively. Overall, for head and neck, the FFF beam plans achieved mean dose reduction of up to 5%, 7% and 9%, respectively for above organs at risk. For lung and prostate cases, the FFF beams provided lower or comparable NTCP values to organ-at-risk (OAR) compared to the flattened beam for all plans. Conclusions: In general, we observed treatment plans utilizing FFF beams can improve dose sparing to OARs without compromising the target coverage. Significant dose sparing effect is obtained for head and neck cancer cases, especially for the cases with relatively large field sizes (about 16x20 cm^2). For lung and prostate cases, compared to the flattened beam, the FFF beam based treatment plans provide lower or comparable dose to most OARs.
△ Less
Submitted 16 June, 2015;
originally announced June 2015.
